🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 13 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
21/01/2025 14,27 14,36 13,99 14,14 +0,78% 2,59% 767.400
17/01/2025 14,31 14,45 13,94 14,03 -0,64% 3,56% 331.600
16/01/2025 14,25 14,41 13,81 14,12 -0,98% 4,21% 692.000
15/01/2025 14,38 14,52 14,08 14,26 +3,18% 3,09% 513.000
14/01/2025 14,02 14,13 13,64 13,82 -0,79% 3,50% 635.700
13/01/2025 14,00 14,15 13,51 13,93 -1,90% 4,57% 560.900
10/01/2025 14,62 14,72 14,04 14,20 -4,83% 4,65% 574.100
08/01/2025 15,16 15,35 14,92 14,92 -2,10% 2,84% 389.900
07/01/2025 14,86 15,62 14,86 15,24 +2,49% 5,08% 625.800
06/01/2025 15,03 15,41 14,87 14,87 -1,26% 3,59% 654.800
03/01/2025 15,27 15,59 15,03 15,06 -0,46% 3,67% 385.900
02/01/2025 15,18 15,61 14,80 15,13 +1,61% 5,34% 588.800
31/12/2024 14,86 15,17 14,62 14,89 -0,13% 3,70% 451.300
30/12/2024 15,28 15,28 14,65 14,91 -2,36% 4,12% 647.800
27/12/2024 15,70 15,73 14,94 15,27 -3,54% 5,03% 482.300
26/12/2024 15,86 16,08 15,68 15,83 -0,50% 2,52% 357.500
24/12/2024 16,00 16,00 15,46 15,91 -0,31% 3,37% 157.200
23/12/2024 15,56 15,97 15,33 15,96 +2,97% 4,11% 597.500
20/12/2024 15,11 15,99 15,10 15,50 +0,26% 5,89% 2.023.300
19/12/2024 15,17 15,75 14,78 15,46 +1,91% 6,43% 658.800
18/12/2024 16,07 16,31 15,16 15,17 -5,66% 7,16% 857.500
17/12/2024 16,26 16,44 15,78 16,08 -2,60% 4,06% 805.400
16/12/2024 15,95 16,54 15,75 16,51 +2,67% 4,95% 605.300
13/12/2024 17,13 17,27 16,02 16,08 -6,29% 7,30% 793.800
12/12/2024 17,70 17,82 17,02 17,16 -4,45% 4,52% 847.200
11/12/2024 17,46 18,07 17,11 17,96 +3,10% 5,50% 541.800
10/12/2024 17,16 17,66 16,83 17,42 -0,29% 4,84% 412.200
09/12/2024 17,64 17,96 17,25 17,47 +1,04% 4,01% 501.200
06/12/2024 17,26 18,09 16,96 17,29 +1,05% 6,55% 628.300
05/12/2024 16,80 17,71 16,79 17,11 +0,06% 5,48% 913.700